Previous 10 | Next 10 |
ROCKVILLE, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), today announced it will be featured as a presenting company at the H.C. Wainwright 24 th Annual Global Investment Conference. The conference is being held as a hybrid in-person and...
The Nasdaq has granted to the medicine company OpGen ( NASDAQ: OPGN ) a 180-day extension to regain compliance with the stock exchange's minimum bid price requirement. OpGen now has until Feb. 27, 2023, to regain compliance. The compliance will be regained if...
ROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has received written notification from t...
Expanding services and offerings to the infectious disease community throughout the U.S. provides revenue growth opportunity Services at launch include rapid turnaround sequencing of clinical isolates, unique and differentiated interpretative services and the proprietary AREScloud web...
OpGen, Inc. (OPGN) Q2 2022 Earnings Conference Call August 11, 2022 04:30 PM ET Company Participants Alyssa Factor - Investor Relations Associate, Edison Group Oliver Schacht - President & Chief Executive Officer Albert Weber - Chief Financial Officer C...
OpGen press release ( NASDAQ: OPGN ): Q2 GAAP EPS of -$0.13 beats by $0.02 . Revenue of $1M (+23.5% Y/Y) in-line. For further details see: OpGen GAAP EPS of -$0.13 beats by $0.02, revenue of $1M in-line
Total Q2 2022 revenues of $1.0 million with product sales a key growth driver First two commercial customer contracts for Acuitas AMR Gene Panel signed in June and July 2022 Requested additional 180-day period to regain compliance with Nasdaq minimum bid price rule ...
ROCKVILLE, Md., July 28, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 2022 financial results after the close of the U.S. financial mark...
Collaborators aim to develop and evaluate computation tools, including predictive models for whole genome sequencing-based antibiotic susceptibility testing (wgsAST) Ares plans to strategically expand its proprietary AMR knowledgebase ARESdb with data collected during the collaboratio...
OpGen ( NASDAQ: OPGN ) announced Friday the preliminary second quarter estimates with revenue expected to be $1M, up from $0.8M in prior year. "We are excited by the progress made in the second quarter, especially the fact that in June we signed the first commercial contra...
News, Short Squeeze, Breakout and More Instantly...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...